NCT05121844Active, not recruiting
Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform
Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform: Comprehensive Weight Optimization Program and Customized Lifestyle Modifications
Source: ClinicalTrials.gov · Last updated 24 Aug 2025
Brief summary (registry, in English)
Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity, pre-diabetes and diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools that help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and targeted coaching and nutrition education will assist with weight optimization goals in the general (non-diabetic) population using the Signos mHealth platform, with associated health benefits.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 31187 (estimated)
- First submitted
- 4 Nov 2021
- Start date
- 2 Nov 2021
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Signos Inc
- Diseases
- Obesity
- NCT number
- NCT05121844
What you commit to
- Study type: Interventional
- Planned participants: 31187
- From 2 Nov 2021 to the primary completion date, 1 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current medical diagnosis of an eating disorder (anorexia or bulimia) or previously struggled with disordered eating behaviors with current BMI less than 24
- Currently taking any of the following medications: Hydroxyurea, insulin, sulfonylureas, or medications prescribed specifically for the treatment of diagnosed diabetes
Other illness
- Medical diagnosis of Type 1 Diabetes
- Medical diagnosis of Type 2 Diabetes
- Medical conditions (e.g., such as seizure disorder) requiring a specific medical diet.
- Inborn errors of metabolism such as phenylketonuria (PKU), glycogen storage disease, fructose intolerance, Maple Sugar Urine Disease (MSUD).
- Chronic or severe disease (e.g, chronic obstructive pulmonary disease \[COPD\], coronary artery disease, cerebrovascular accident \[CVA\], or cardiac arrhythmia) that would preclude a subject from safely participating in dietary recommendations and/or physical activity
- History of Gastric bypass or other bariatric surgery
- History of 10 or more soft tissue skin infections (such as cellulitis or abscesses)
Other
- Intolerable skin reaction from adhesive
- Vulnerable populations such as minors, prisoners, or pregnant women will not be enrolled in this study. Women who become pregnant will be excluded at that time.
- Inability or unwillingness of subject to give informed consent
Who the study is looking for
- 18 years and above
- Own a smartphone and be willing to install the Signos App to use the app, receive messages or notifications, and input weight and other data.
- Willingness to complete questionaries or other surveys
- Able to speak and read English
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Signos Coordinator of this site? Confirm its status | Palo Alto | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.